Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

21-25 of 42 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Trial type

Location

Mutation

Therapeutic category

Virtual Care in CF (VIRTUAL-CF)

This study aims to find out if CF patients benefit from ‘virtual care’ while they are receiving intravenous (IV) antibiotics in the community. ‘Virtual care’ is a term that we are using to describe the provision of regular videoconferencing with the CF team as well as equipment to allow patients to monitor their own lung function and oxygen saturations.

Read more Pilot/Feasibility
  • Trial Reference Number

    46773

  • Age

    18+

  • Length of participation

    2 weeks

  • Trial status

    Open

  • Therapeutic category

    Other

MAGIC- a self-management education programme for people with CFRD

Cystic fibrosis (CF) is a life-shortening genetic disease that damages many of the body’s organs, including the lungs, pancreas and digestive system. Cystic fibrosis related diabetes (CFRD) is the most common complication of CF, affecting 45-50% of adults. CFRD is different from type 1 and 2 diabetes and needs specialist dietary and clinical management. CFRD has a significant effect on nutrition, lung function and survival. The need to educate people with CFRD is important because, keeping blood glucose controlled results in improvements in nutrition, and reduces the development of long term complications from CFRD, including death. NICE recommends that everyone with diabetes should be offered a place on a diabetes self-management education (DSME) programme. However, there are currently no DSME programmes specifically for people with CFRD and there is little evidence to base them on. This study, informed by the Medical Research Council’s framework for developing complex interventions, aims to develop an evidence-based self-management education programme for people with CFRD that, will be called MAGIC (Managing Abnormal Glucose In Cystic fibrosis). Stage one is a synthesis of qualitative studies and qualitative patient interviews. This will identify patients’ experiences of living with CFRD and their barriers and facilitators to CFRD self-management. It will help establish what educational input people with CFRD want and identify the skills and knowledge people with CFRD require. Stage one will inform stage two. Stage two is the development of the MAGIC programme by a working group of lay members and healthcare professionals. The MAGIC programme will be evaluated with ten CFRD patients within the hospital. This will help inform future studies required to evaluate its effectiveness (feasibility study), and if appropriate a randomised control trial for evaluating the cost-effectiveness and the impact on well-being and survival of the MAGIC programme at a national level.

Read more Not Applicable
  • Trial Reference Number

    94784

  • Length of participation

    2 days

  • Trial status

    Open to recruitment

  • Therapeutic category

    Nutritional-GI

Flamingo

Cystic fibrosis is caused by changes in the genes of your DNA (Deoxyribonucleic Acid) encoding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. These changes cause the CFTR to stop working as it should. CFTR is a protein present in some specific cells of the body and its correct functioning is important for those cells. GLPG2222 is being studied for treatment of cystic fibrosis. The study drug is designed to improve the amount and function of CFTR, which may improve some of the symptoms of cystic fibrosis. The purpose of this study is to find out whether GLPG2222, taken by mouth as tablet once a day, is safe, well-tolerated and effective in improving your signs and symptoms of cystic fibrosis. The study will also evaluate how the body takes in and breaks down the study drug (GLPG2222). The amount of drug in your blood will be measured at specific study visits after you start taking the drug. These measurements will show how quickly the drug is taken up by the body, how quickly it is broken down, when it reaches a steady level in the blood, and how long it stays in the body.

Read more
  • Trial Reference Number

    94989

  • Mutation

    Two copies of F508del (delta F508)

  • Age

    18+

  • Length of participation

    6 - 10 weeks

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

A study of FDL169 in subjects with Cystic Fibrosis

This is a randomized, placebo controlled, double-blinded study. 24 CF subjects will be assigned randomly to two groups, active drug or placebo. Three doses of FDL169 or placebo will be given 3 times a day for 28 days. The aim of this clinical study is to test how well CF subjects tolerate FDL169. In addition, the study will also test how subjects’ bodies absorb and digest FDL169 by measuring study subjects’ blood at specific intervals after taking the tablet orally.

Read more Phase I
  • Trial Reference Number

    90508

  • Mutation

    Two copies of F508del (delta F508)

  • Age

    18+

  • Length of participation

    28 days

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease. There are six different potential dosing regimens, including one that is placebo.

Phase II
  • Trial Reference Number

    101870

  • Age

    18+

  • Length of participation

    3 weeks

  • Trial status

    Open to recruitment

  • Therapeutic category

    Mucociliary Clearance

21-25 of 42 results for all trials